Evaluation and Management of the Child and Adult with Fontan Circulation: A Scientific Statement from the American Heart Association

Jack Rychik, Andrew M. Atz, David S. Celermajer, Barbara J. Deal, Michael A. Gatzoulis, Marc H. Gewillig, Tain Yen Hsia, Daphne T. Hsu, Adrienne H. Kovacs, Brian W. McCrindle, Jane W. Newburger, Nancy A. Pike, Mark Rodefeld, David N. Rosenthal, Kurt R. Schumacher, Bradley S. Marino, Karen Stout, Gruschen Veldtman, Adel K. Younoszai, Yves D'Udekem

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

It has been 50 years since Francis Fontan pioneered the operation that today bears his name. Initially designed for patients with tricuspid atresia, this procedure is now offered for a vast array of congenital cardiac lesions when a circulation with 2 ventricles cannot be achieved. As a result of technical advances and improvements in patient selection and perioperative management, survival has steadily increased, and it is estimated that patients operated on today may hope for a 30-year survival of >80%. Up to 70 000 patients may be alive worldwide today with Fontan circulation, and this population is expected to double in the next 20 years. In the absence of a subpulmonary ventricle, Fontan circulation is characterized by chronically elevated systemic venous pressures and decreased cardiac output. The addition of this acquired abnormal circulation to innate abnormalities associated with single-ventricle congenital heart disease exposes these patients to a variety of complications. Circulatory failure, ventricular dysfunction, atrioventricular valve regurgitation, arrhythmia, protein-losing enteropathy, and plastic bronchitis are potential complications of the Fontan circulation. Abnormalities in body composition, bone structure, and growth have been detected. Liver fibrosis and renal dysfunction are common and may progress over time. Cognitive, neuropsychological, and behavioral deficits are highly prevalent. As a testimony to the success of the current strategy of care, the proportion of adults with Fontan circulation is increasing. Healthcare providers are ill-prepared to tackle these challenges, as well as specific needs such as contraception and pregnancy in female patients. The role of therapies such as cardiovascular drugs to prevent and treat complications, heart transplantation, and mechanical circulatory support remains undetermined. There is a clear need for consensus on how best to follow up patients with Fontan circulation and to treat their complications. This American Heart Association statement summarizes the current state of knowledge on the Fontan circulation and its consequences. A proposed surveillance testing toolkit provides recommendations for a range of acceptable approaches to follow-up care for the patient with Fontan circulation. Gaps in knowledge and areas for future focus of investigation are highlighted, with the objective of laying the groundwork for creating a normal quality and duration of life for these unique individuals.

Original languageEnglish (US)
Pages (from-to)E234-E284
JournalCirculation
Volume140
Issue number6
DOIs
StatePublished - Aug 6 2019

Fingerprint

Hope
Tricuspid Atresia
Protein-Losing Enteropathies
Fontan Procedure
Ventricular Dysfunction
Cardiovascular Agents
Aftercare
Venous Pressure
Survival
Bronchitis
Bone Development
Heart Transplantation
Body Composition
Contraception
Liver Cirrhosis
Cardiac Output
Health Personnel
Patient Selection
Names
Cardiac Arrhythmias

Keywords

  • AHA Scientific Statements
  • congenital heart defects
  • Fontan procedure
  • quality of life

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Rychik, J., Atz, A. M., Celermajer, D. S., Deal, B. J., Gatzoulis, M. A., Gewillig, M. H., ... D'Udekem, Y. (2019). Evaluation and Management of the Child and Adult with Fontan Circulation: A Scientific Statement from the American Heart Association. Circulation, 140(6), E234-E284. https://doi.org/10.1161/CIR.0000000000000696

Evaluation and Management of the Child and Adult with Fontan Circulation : A Scientific Statement from the American Heart Association. / Rychik, Jack; Atz, Andrew M.; Celermajer, David S.; Deal, Barbara J.; Gatzoulis, Michael A.; Gewillig, Marc H.; Hsia, Tain Yen; Hsu, Daphne T.; Kovacs, Adrienne H.; McCrindle, Brian W.; Newburger, Jane W.; Pike, Nancy A.; Rodefeld, Mark; Rosenthal, David N.; Schumacher, Kurt R.; Marino, Bradley S.; Stout, Karen; Veldtman, Gruschen; Younoszai, Adel K.; D'Udekem, Yves.

In: Circulation, Vol. 140, No. 6, 06.08.2019, p. E234-E284.

Research output: Contribution to journalReview article

Rychik, J, Atz, AM, Celermajer, DS, Deal, BJ, Gatzoulis, MA, Gewillig, MH, Hsia, TY, Hsu, DT, Kovacs, AH, McCrindle, BW, Newburger, JW, Pike, NA, Rodefeld, M, Rosenthal, DN, Schumacher, KR, Marino, BS, Stout, K, Veldtman, G, Younoszai, AK & D'Udekem, Y 2019, 'Evaluation and Management of the Child and Adult with Fontan Circulation: A Scientific Statement from the American Heart Association', Circulation, vol. 140, no. 6, pp. E234-E284. https://doi.org/10.1161/CIR.0000000000000696
Rychik, Jack ; Atz, Andrew M. ; Celermajer, David S. ; Deal, Barbara J. ; Gatzoulis, Michael A. ; Gewillig, Marc H. ; Hsia, Tain Yen ; Hsu, Daphne T. ; Kovacs, Adrienne H. ; McCrindle, Brian W. ; Newburger, Jane W. ; Pike, Nancy A. ; Rodefeld, Mark ; Rosenthal, David N. ; Schumacher, Kurt R. ; Marino, Bradley S. ; Stout, Karen ; Veldtman, Gruschen ; Younoszai, Adel K. ; D'Udekem, Yves. / Evaluation and Management of the Child and Adult with Fontan Circulation : A Scientific Statement from the American Heart Association. In: Circulation. 2019 ; Vol. 140, No. 6. pp. E234-E284.
@article{11f10d45cbbc4124a1e257d97a69afef,
title = "Evaluation and Management of the Child and Adult with Fontan Circulation: A Scientific Statement from the American Heart Association",
abstract = "It has been 50 years since Francis Fontan pioneered the operation that today bears his name. Initially designed for patients with tricuspid atresia, this procedure is now offered for a vast array of congenital cardiac lesions when a circulation with 2 ventricles cannot be achieved. As a result of technical advances and improvements in patient selection and perioperative management, survival has steadily increased, and it is estimated that patients operated on today may hope for a 30-year survival of >80{\%}. Up to 70 000 patients may be alive worldwide today with Fontan circulation, and this population is expected to double in the next 20 years. In the absence of a subpulmonary ventricle, Fontan circulation is characterized by chronically elevated systemic venous pressures and decreased cardiac output. The addition of this acquired abnormal circulation to innate abnormalities associated with single-ventricle congenital heart disease exposes these patients to a variety of complications. Circulatory failure, ventricular dysfunction, atrioventricular valve regurgitation, arrhythmia, protein-losing enteropathy, and plastic bronchitis are potential complications of the Fontan circulation. Abnormalities in body composition, bone structure, and growth have been detected. Liver fibrosis and renal dysfunction are common and may progress over time. Cognitive, neuropsychological, and behavioral deficits are highly prevalent. As a testimony to the success of the current strategy of care, the proportion of adults with Fontan circulation is increasing. Healthcare providers are ill-prepared to tackle these challenges, as well as specific needs such as contraception and pregnancy in female patients. The role of therapies such as cardiovascular drugs to prevent and treat complications, heart transplantation, and mechanical circulatory support remains undetermined. There is a clear need for consensus on how best to follow up patients with Fontan circulation and to treat their complications. This American Heart Association statement summarizes the current state of knowledge on the Fontan circulation and its consequences. A proposed surveillance testing toolkit provides recommendations for a range of acceptable approaches to follow-up care for the patient with Fontan circulation. Gaps in knowledge and areas for future focus of investigation are highlighted, with the objective of laying the groundwork for creating a normal quality and duration of life for these unique individuals.",
keywords = "AHA Scientific Statements, congenital heart defects, Fontan procedure, quality of life",
author = "Jack Rychik and Atz, {Andrew M.} and Celermajer, {David S.} and Deal, {Barbara J.} and Gatzoulis, {Michael A.} and Gewillig, {Marc H.} and Hsia, {Tain Yen} and Hsu, {Daphne T.} and Kovacs, {Adrienne H.} and McCrindle, {Brian W.} and Newburger, {Jane W.} and Pike, {Nancy A.} and Mark Rodefeld and Rosenthal, {David N.} and Schumacher, {Kurt R.} and Marino, {Bradley S.} and Karen Stout and Gruschen Veldtman and Younoszai, {Adel K.} and Yves D'Udekem",
year = "2019",
month = "8",
day = "6",
doi = "10.1161/CIR.0000000000000696",
language = "English (US)",
volume = "140",
pages = "E234--E284",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Evaluation and Management of the Child and Adult with Fontan Circulation

T2 - A Scientific Statement from the American Heart Association

AU - Rychik, Jack

AU - Atz, Andrew M.

AU - Celermajer, David S.

AU - Deal, Barbara J.

AU - Gatzoulis, Michael A.

AU - Gewillig, Marc H.

AU - Hsia, Tain Yen

AU - Hsu, Daphne T.

AU - Kovacs, Adrienne H.

AU - McCrindle, Brian W.

AU - Newburger, Jane W.

AU - Pike, Nancy A.

AU - Rodefeld, Mark

AU - Rosenthal, David N.

AU - Schumacher, Kurt R.

AU - Marino, Bradley S.

AU - Stout, Karen

AU - Veldtman, Gruschen

AU - Younoszai, Adel K.

AU - D'Udekem, Yves

PY - 2019/8/6

Y1 - 2019/8/6

N2 - It has been 50 years since Francis Fontan pioneered the operation that today bears his name. Initially designed for patients with tricuspid atresia, this procedure is now offered for a vast array of congenital cardiac lesions when a circulation with 2 ventricles cannot be achieved. As a result of technical advances and improvements in patient selection and perioperative management, survival has steadily increased, and it is estimated that patients operated on today may hope for a 30-year survival of >80%. Up to 70 000 patients may be alive worldwide today with Fontan circulation, and this population is expected to double in the next 20 years. In the absence of a subpulmonary ventricle, Fontan circulation is characterized by chronically elevated systemic venous pressures and decreased cardiac output. The addition of this acquired abnormal circulation to innate abnormalities associated with single-ventricle congenital heart disease exposes these patients to a variety of complications. Circulatory failure, ventricular dysfunction, atrioventricular valve regurgitation, arrhythmia, protein-losing enteropathy, and plastic bronchitis are potential complications of the Fontan circulation. Abnormalities in body composition, bone structure, and growth have been detected. Liver fibrosis and renal dysfunction are common and may progress over time. Cognitive, neuropsychological, and behavioral deficits are highly prevalent. As a testimony to the success of the current strategy of care, the proportion of adults with Fontan circulation is increasing. Healthcare providers are ill-prepared to tackle these challenges, as well as specific needs such as contraception and pregnancy in female patients. The role of therapies such as cardiovascular drugs to prevent and treat complications, heart transplantation, and mechanical circulatory support remains undetermined. There is a clear need for consensus on how best to follow up patients with Fontan circulation and to treat their complications. This American Heart Association statement summarizes the current state of knowledge on the Fontan circulation and its consequences. A proposed surveillance testing toolkit provides recommendations for a range of acceptable approaches to follow-up care for the patient with Fontan circulation. Gaps in knowledge and areas for future focus of investigation are highlighted, with the objective of laying the groundwork for creating a normal quality and duration of life for these unique individuals.

AB - It has been 50 years since Francis Fontan pioneered the operation that today bears his name. Initially designed for patients with tricuspid atresia, this procedure is now offered for a vast array of congenital cardiac lesions when a circulation with 2 ventricles cannot be achieved. As a result of technical advances and improvements in patient selection and perioperative management, survival has steadily increased, and it is estimated that patients operated on today may hope for a 30-year survival of >80%. Up to 70 000 patients may be alive worldwide today with Fontan circulation, and this population is expected to double in the next 20 years. In the absence of a subpulmonary ventricle, Fontan circulation is characterized by chronically elevated systemic venous pressures and decreased cardiac output. The addition of this acquired abnormal circulation to innate abnormalities associated with single-ventricle congenital heart disease exposes these patients to a variety of complications. Circulatory failure, ventricular dysfunction, atrioventricular valve regurgitation, arrhythmia, protein-losing enteropathy, and plastic bronchitis are potential complications of the Fontan circulation. Abnormalities in body composition, bone structure, and growth have been detected. Liver fibrosis and renal dysfunction are common and may progress over time. Cognitive, neuropsychological, and behavioral deficits are highly prevalent. As a testimony to the success of the current strategy of care, the proportion of adults with Fontan circulation is increasing. Healthcare providers are ill-prepared to tackle these challenges, as well as specific needs such as contraception and pregnancy in female patients. The role of therapies such as cardiovascular drugs to prevent and treat complications, heart transplantation, and mechanical circulatory support remains undetermined. There is a clear need for consensus on how best to follow up patients with Fontan circulation and to treat their complications. This American Heart Association statement summarizes the current state of knowledge on the Fontan circulation and its consequences. A proposed surveillance testing toolkit provides recommendations for a range of acceptable approaches to follow-up care for the patient with Fontan circulation. Gaps in knowledge and areas for future focus of investigation are highlighted, with the objective of laying the groundwork for creating a normal quality and duration of life for these unique individuals.

KW - AHA Scientific Statements

KW - congenital heart defects

KW - Fontan procedure

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=85072030623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072030623&partnerID=8YFLogxK

U2 - 10.1161/CIR.0000000000000696

DO - 10.1161/CIR.0000000000000696

M3 - Review article

C2 - 31256636

AN - SCOPUS:85072030623

VL - 140

SP - E234-E284

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 6

ER -